• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.

作者信息

Kimura Hideharu, Araya Tomoyuki, Yoneda Taro, Shirasaki Hiroki, Kurokawa Koji, Sakai Tamami, Koba Hayato, Tambo Yuichi, Nishikawa Shingo, Sone Takashi, Kasahara Kazuo

机构信息

Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8641, Japan.

Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, 920-8650, Japan.

出版信息

Cancer Commun (Lond). 2019 Nov 21;39(1):78. doi: 10.1186/s40880-019-0423-3.

DOI:10.1186/s40880-019-0423-3
PMID:31753015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6873691/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b80/6873691/93831e62fe0d/40880_2019_423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b80/6873691/93831e62fe0d/40880_2019_423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b80/6873691/93831e62fe0d/40880_2019_423_Fig1_HTML.jpg

相似文献

1
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.在先前接受过治疗的晚期非小细胞肺癌患者中，因肿瘤进展以外的原因停用纳武利尤单抗治疗后出现的长期反应。
Cancer Commun (Lond). 2019 Nov 21;39(1):78. doi: 10.1186/s40880-019-0423-3.
2
Nivolumab improves survival for patients with advanced lung cancer.纳武单抗可提高晚期肺癌患者的生存率。
Cancer. 2017 Sep 1;123(17):3211. doi: 10.1002/cncr.30930.
3
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.肝转移与接受纳武利尤单抗治疗的非小细胞肺癌患者的无进展生存期较差相关。
J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027.
4
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.纳武利尤单抗治疗晚期非小细胞肺癌的真实世界疗效和安全性：一项回顾性多中心分析。
Clin Lung Cancer. 2018 May;19(3):e349-e358. doi: 10.1016/j.cllc.2018.01.001. Epub 2018 Jan 5.
5
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.纳武利尤单抗治疗晚期非小细胞肺癌患者进展后疗效和安全性的研究
Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27.
6
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.开发纳武利尤单抗治疗晚期非小细胞肺癌患者临床结局的预测模型。
Clin Lung Cancer. 2018 May;19(3):280-288.e4. doi: 10.1016/j.cllc.2017.12.007. Epub 2017 Dec 21.
7
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.纳武利尤单抗治疗晚期非小细胞肺癌停药后的进展后生存：一项回顾性研究。
PLoS One. 2018 Aug 28;13(8):e0203070. doi: 10.1371/journal.pone.0203070. eCollection 2018.
8
Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.真实世界实践中纳武利尤单抗治疗晚期非小细胞肺癌患者的临床结局，重点关注超进展性疾病。
J Cancer Res Clin Oncol. 2020 Nov;146(11):3025-3036. doi: 10.1007/s00432-020-03293-9. Epub 2020 Jun 24.
9
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.纳武利尤单抗单药二线治疗晚期非小细胞肺癌患者的后进展生存期对总生存期的临床影响。
Thorac Cancer. 2021 Apr;12(8):1171-1179. doi: 10.1111/1759-7714.13886. Epub 2021 Feb 24.
10
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.免疫相关不良事件对纳武利尤单抗治疗的晚期非小细胞肺癌患者生存的影响：多机构分析的长期结果。
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

引用本文的文献

1
Statins as potential adjuvant therapy in lung cancer: a narrative review.他汀类药物作为肺癌潜在辅助治疗的叙述性综述。
J Thorac Dis. 2025 May 30;17(5):3433-3449. doi: 10.21037/jtd-2025-66. Epub 2025 May 19.
2
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody.乐伐替尼增强抗PD-1抗体的抗肿瘤免疫力。
Int J Clin Oncol. 2025 Apr;30(4):666-673. doi: 10.1007/s10147-025-02721-5. Epub 2025 Feb 22.
3
A stage IIIA lung adenocarcinoma case achieving pathological response with only one cycle of preoperative nivolumab combination chemotherapy.

本文引用的文献

1
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).纳武利尤单抗对比多西他赛用于既往接受过治疗的晚期非小细胞肺癌患者：两项随机、开放标签、III期试验（CheckMate 017和CheckMate 057）的两年结果
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.
2
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.免疫相关不良反应与纳武利尤单抗治疗非小细胞肺癌疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.
3
一例IIIA期肺腺癌患者仅接受一个周期的术前纳武单抗联合化疗即达到病理缓解。
Gen Thorac Cardiovasc Surg Cases. 2025 Feb 3;4(1):6. doi: 10.1186/s44215-025-00187-5.
4
Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study.纳武利尤单抗联合化疗用于FGFR2和PD-L1共表达的转移性胃癌：一项前瞻性2期NIVOFGFR2研究
J Gastrointest Cancer. 2025 Jan 11;56(1):40. doi: 10.1007/s12029-025-01172-5.
5
Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.非小细胞肺癌的免疫治疗：关于一线治疗、特殊人群和再挑战的改良德尔菲调查共识
Biomedicines. 2024 Nov 29;12(12):2742. doi: 10.3390/biomedicines12122742.
6
Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group.国际老年放疗组针对不适合或拒绝手术及化疗的局部晚期非转移性非小细胞肺癌老年患者的免疫治疗与放疗：一项实用建议
Cancers (Basel). 2024 Sep 9;16(17):3112. doi: 10.3390/cancers16173112.
7
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis.停用免疫检查点抑制剂的晚期实体瘤患者的结局：一项系统评价和荟萃分析。
EClinicalMedicine. 2024 Jun 20;73:102681. doi: 10.1016/j.eclinm.2024.102681. eCollection 2024 Jul.
8
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.延长nivolumab 的给药间隔：未选择癌症患者的基于模型的模拟。
Br J Cancer. 2024 May;130(11):1866-1874. doi: 10.1038/s41416-024-02659-x. Epub 2024 Mar 26.
9
The efficacy of immune checkpoint inhibitors following discontinuation for long-term response or toxicity in advanced or metastatic non-small-cell lung cancers: A retrospective study.晚期或转移性非小细胞肺癌中免疫检查点抑制剂停药后长期反应或毒性的疗效：一项回顾性研究。
Health Sci Rep. 2024 Jan 25;7(1):e1825. doi: 10.1002/hsr2.1825. eCollection 2024 Jan.
10
Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC).新辅助免疫化疗在可切除的晚期非小细胞肺癌（NSCLC）中的疗效及手术相关安全性评估。
Front Oncol. 2023 Dec 22;13:1239451. doi: 10.3389/fonc.2023.1239451. eCollection 2023.
Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
纳武单抗治疗停止后肿瘤体积的长期缩小。
Lung Cancer. 2017 Jun;108:7-8. doi: 10.1016/j.lungcan.2017.02.013. Epub 2017 Feb 23.
4
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.转移性非小细胞肺癌患者中纳武单抗相关皮肤反应的特征分析
Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.
5
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
6
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
7
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
8
Reassessing target antigens for adoptive T-cell therapy.重新评估过继性T细胞疗法的靶抗原。
Nat Biotechnol. 2013 Nov;31(11):999-1008. doi: 10.1038/nbt.2725. Epub 2013 Oct 20.